Featured News

With your help, we have invested significant resources into changing that reality in Washington, DC, and we are beginning to see a return on that investment.

Thank you to Schär for sponsoring our upcoming Patient Education and Advocacy Summit. For over 35 years, Schär has been dedicated to the celiac and gluten-sensitive communities by providing a safe, flavorful, and quality line of gluten-free products. Learn more about Schär’s collection of gluten-free goods.

Initial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.

I want to share with you highlights of our advocacy plans for 2021. Our work in Washington, DC, with Congress, with the NIH, FDA, and other agencies, is critical in the pursuit of treatments and a cure for celiac disease.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

A new study suggests a high dose of gluten might protect infants from celiac disease. However, other experts warn that the evidence shows a benefit only for introducing normal amounts of wheat to breastfed babies 4-6 months old.

Celiac Disease Foundation Young Investigator Award recipient Jocelyn Silvester, MD, publishes “A new diagnostic paradigm for celiac disease.”

The Celiac Disease Foundation’s article, “New Legislation Aims to Extend Nutrition Care to Chronic Conditions” was featured in Future of Personal Health.